ESC 365 - Device-detected atrial fibrillation: does thromboembolic risk affect decision-making on anticoagulation management?

EHRA Premium Access

Device-detected atrial fibrillation: does thromboembolic risk affect decision-making on anticoagulation management?

Session: Stroke prevention in clinical and subclinical atrial fibrillation

Topic: Stroke in Atrial Fibrillation

Speaker: Doctor N. Becher (Hamburg, DE)

Event: EHRA 2025

Congress Presentation

Add to my library

About the speaker

Doctor Nina Becher

University Heart and Vascular Centre Hamburg (UHZ), Hamburg (Germany)

3 presentations

0 follower

3 more presentations in this session

Device-detected atrial fibrillation: does episode duration affect decision-making on anticoagulation management?

Speaker: Doctor A. Verma (Montreal, CA)

When should we consider discontinuation of oral anticoagulation following 'successful' atrial fibrillation ablation?

Speaker: Doctor J. van den Bruck (Cologne, DE)

Left atrial appendage thrombus despite therapeutic oral anticoagulation: how should we proceed?

Speaker: Professor V. Roldan-Schilling (Murcia, ES)

Access the full session

Stroke prevention in clinical and subclinical atrial fibrillation

Speakers: Doctor N. Becher, Doctor A. Verma, Doctor J. van den Bruck, Professor V. Roldan-Schilling

About the event

EHRA 2025

30 March - 1 April 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources